# Progyny, Inc.: overview

PGNY · Nasdaq · CIK 1551306 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/pgny.md) · [Financials](/companies/pgny/financials.md) · [Filings](/companies/pgny/filings.md) · [Insiders](/companies/pgny/insiders.md)

Latest reported revenue: [$350.5m](/filings/0001551306-26-000140.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 7, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001551306-26-000140).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [287](/filings/0001551306-26-000020.md) | [298](/filings/0001551306-26-000020.md) | [324](/filings/0001551306-26-000068.md) | [333](/filings/0001551306-26-000140.md) | [313](/filings/0001551306-26-000020.md) | [318](/filings/0001551306-26-000020.md) | [329](/filings/0001551306-26-000068.md) | [351](/filings/0001551306-26-000140.md) |
| Gross margin | % | [20.7%](/filings/0001551306-26-000020.md) | [21.3%](/filings/0001551306-26-000020.md) | [23.4%](/filings/0001551306-26-000068.md) | [23.7%](/filings/0001551306-26-000140.md) | [23.2%](/filings/0001551306-26-000020.md) | [24.1%](/filings/0001551306-26-000020.md) | [25.3%](/filings/0001551306-26-000068.md) | [25.5%](/filings/0001551306-26-000140.md) |
| Operating margin | % | [4.3%](/filings/0001551306-26-000020.md) | [5.3%](/filings/0001551306-26-000020.md) | [7.5%](/filings/0001551306-26-000068.md) | [7.3%](/filings/0001551306-26-000140.md) | [6.9%](/filings/0001551306-26-000020.md) | [4.8%](/filings/0001551306-26-000020.md) | [10.8%](/filings/0001551306-26-000068.md) | [11.4%](/filings/0001551306-26-000140.md) |
| Net margin | % | [3.6%](/filings/0001551306-26-000020.md) | [3.5%](/filings/0001551306-26-000020.md) | [4.6%](/filings/0001551306-26-000068.md) | [5.1%](/filings/0001551306-26-000140.md) | [4.4%](/filings/0001551306-26-000020.md) | [3.9%](/filings/0001551306-26-000020.md) | [7.4%](/filings/0001551306-26-000068.md) | [8.0%](/filings/0001551306-26-000140.md) |
| Diluted EPS | $ per share | [0.11](/filings/0001551306-26-000020.md) | [0.12](/filings/0001551306-26-000020.md) | [0.17](/filings/0001551306-26-000068.md) | [0.19](/filings/0001551306-26-000140.md) | [0.15](/filings/0001551306-26-000020.md) | [0.14](/filings/0001551306-26-000020.md) | [0.29](/filings/0001551306-26-000068.md) | [0.34](/filings/0001551306-26-000140.md) |
| Free cash flow | $m | [42.7 d](/filings/0001551306-25-000190.md) | [50.3 d](/filings/0001551306-26-000020.md) | [47.0](/filings/0001551306-26-000068.md) | [50.2 d](/filings/0001551306-26-000140.md) | [46.0 d](/filings/0001551306-25-000190.md) | [48.6 d](/filings/0001551306-26-000020.md) | [39.6](/filings/0001551306-26-000068.md) | [44.2 d](/filings/0001551306-26-000140.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [501](/filings/0001551306-24-000031.md) | [787](/filings/0001551306-25-000040.md) | [1,089](/filings/0001551306-26-000020.md) | [1,167](/filings/0001551306-26-000020.md) | [1,289](/filings/0001551306-26-000020.md) |
| Gross margin | % | [22.4%](/filings/0001551306-24-000031.md) | [21.3%](/filings/0001551306-25-000040.md) | [21.9%](/filings/0001551306-26-000020.md) | [21.7%](/filings/0001551306-26-000020.md) | [23.6%](/filings/0001551306-26-000020.md) |
| Operating margin | % | [6.5%](/filings/0001551306-24-000031.md) | [3.0%](/filings/0001551306-25-000040.md) | [5.7%](/filings/0001551306-26-000020.md) | [5.8%](/filings/0001551306-26-000020.md) | [6.6%](/filings/0001551306-26-000020.md) |
| Net margin | % | [13.1%](/filings/0001551306-24-000031.md) | [3.9%](/filings/0001551306-25-000040.md) | [5.7%](/filings/0001551306-26-000020.md) | [4.7%](/filings/0001551306-26-000020.md) | [4.5%](/filings/0001551306-26-000020.md) |
| Diluted EPS | $ per share | [0.66](/filings/0001551306-24-000031.md) | [0.30](/filings/0001551306-25-000040.md) | [0.62](/filings/0001551306-26-000020.md) | [0.57](/filings/0001551306-26-000020.md) | [0.65](/filings/0001551306-26-000020.md) |
| Free cash flow | $m | [23.9](/filings/0001551306-24-000031.md) | [77.2](/filings/0001551306-25-000040.md) | [185](/filings/0001551306-26-000020.md) | [174](/filings/0001551306-26-000020.md) | [192](/filings/0001551306-26-000020.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/pgny/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2020-05-20 | [Glaxosmithkline plc](/insiders/1131399.md) | 10% owner | Sale (S) | 4,000,000 | $25.75 | $103.0m | [Form 4](/filings/0001387131-20-005115.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $334.4m | 11,599,921 |  | Reduced −398,546 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $201.9m | 7,004,280 |  | Added +503,461 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $144.7m | 5,019,465 |  | Reduced −272,563 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $92.6m | 3,210,723 |  | Reduced −270,616 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $87.1m | 3,022,859 |  | Reduced −57,434 |
| [AMERIPRISE FINANCIAL INC](/funds/820027.md) | 2026-06-30 | $79.7m | 2,763,514 |  | Reduced −61,817 |
| [FORT WASHINGTON INVESTMENT ADVISORS INC /OH/](/funds/1009016.md) | 2026-06-30 | $73.5m | 2,548,164 |  | Reduced −145,229 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $56.8m | 1,969,208 |  | Reduced −73,757 |
| [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $51.5m | 1,785,717 |  | New +1,785,717 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $48.7m | 1,688,670 |  | Added +115,245 |

## Recent filings

[All 921 filings](/companies/pgny/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-07 | 09:00 ET | [10-Q](/filings/0001551306-26-000140.md) | Quarterly report, period 2026-06-30 | 0001551306-26-000140 |
| 2026-08-06 | 16:10 ET | [8-K](/filings/0001551306-26-000135.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure | 0001551306-26-000135 |
| 2026-05-27 | 09:13 ET | [8-K](/filings/0001551306-26-000109.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results | 0001551306-26-000109 |
| 2026-05-26 | 09:15 ET | [8-K](/filings/0001551306-26-000074.md) | 8.01 Other events | 0001551306-26-000074 |
| 2026-05-08 | 08:50 ET | [10-Q](/filings/0001551306-26-000068.md) | Quarterly report, period 2026-03-31 | 0001551306-26-000068 |
| 2026-05-07 | 16:03 ET | [8-K](/filings/0001551306-26-000062.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure | 0001551306-26-000062 |
| 2026-04-10 | 08:33 ET | [DEF 14A](/filings/0001551306-26-000055.md) | Proxy statement, period 2026-05-21 | 0001551306-26-000055 |
| 2026-03-13 | 16:15 ET | [8-K](/filings/0001551306-26-000040.md) | 8.01 Other events | 0001551306-26-000040 |
| 2026-02-27 | 09:18 ET | [10-K](/filings/0001551306-26-000020.md) | Annual report, period 2025-12-31 | 0001551306-26-000020 |
| 2026-02-26 | 16:05 ET | [8-K](/filings/0001551306-26-000012.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure | 0001551306-26-000012 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001551306-26-000020.md), filed Feb 27, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/d128fa5b-129b-473a-b7ac-522c1043da6d)

## About the filer

- CIK: 1551306
- Tickers: PGNY
- Exchange: Nasdaq
- SIC code: 8090 Services-Misc Health & Allied Services, NEC
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 17:30 ET. No prices; not investment advice.